A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
CONDITION: Skin
GENDER: All
AGE GROUP: 18 to 75 years
TRIAL STATUS: Active, not recruiting
A Phase 3 Randomized, Active-Controlled, Open-Label Study to Evaluate a Switch to an Oral Weekly Islatravir/ Lenacapavir Regimen in People with HIV-1 Who are Virologically Suppressed on Standard of Care
CONDITION: Other
GENDER: All
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting
A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir (B/F/TAF)
CONDITION: Other
GENDER: All
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting
CONDITION: Inflammatory and Immune System
GENDER: Both males and females
AGE GROUP: 18 and above
TRIAL STATUS: Completed
A Phase 3, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety and Immunogenicity of a SARS‑CoV‑2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine with Matrix-M™ Adjuvant and a …
CONDITION: Other
GENDER: All
AGE GROUP: 60 and above
TRIAL STATUS: Active, not recruiting
A Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Trial to Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects without Diabetes Mellitus
CONDITION: Metabolic and Endocrine
GENDER: All
AGE GROUP: 18 to 75 years
TRIAL STATUS: Active, not recruiting
Efficacy and Safety of HB-1 for Panic Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
CONDITION: Mental Health
GENDER: All
AGE GROUP: 18 to 65 years
TRIAL STATUS:
A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of ABI-5366 in Healthy Subjects and in Subjects who are Seropositive for HSV-2 …
CONDITION: Other
GENDER: All
AGE GROUP: 18 to 60 years
TRIAL STATUS:
CONDITION: Inflammatory and Immune System
GENDER: Both males and females
AGE GROUP: 18 and above
TRIAL STATUS: Completed
CONDITION: Infection
GENDER: Males
AGE GROUP: 18 to 50 years
TRIAL STATUS: Closed: follow-up complete
A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of ABI-5366 in Healthy Subjects and in Subjects who are Seropositive for HSV-2 …
CONDITION: Other
GENDER: All
AGE GROUP: 18 to 60 years
TRIAL STATUS: Recruiting
This is a phase III, randomized, multicenter, open-label study which will be performed to evaluate efficacy and safety of oral Gepotidacin compared to intramuscular (IM) ceftriaxone plus oral azithromycin for the treatment …
CONDITION: Infection
GENDER: All
AGE GROUP: 12 and above
TRIAL STATUS: Completed
A seven year plan of enhanced HCV monitoring, primary care–based workforce development, rapid scale-up of HCV treatment and public health policy action in HIV positive individuals within Australia.
CONDITION: Inflammatory and Immune System
GENDER: All
AGE GROUP: 18 and above
TRIAL STATUS: Completed
This Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLAS-2M) study is designed to demonstrate the non-inferior antiviral activity and safety of CAB LA + RPV LA administered every …
CONDITION: Inflammatory and Immune System
GENDER: All
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting
A Phase 2 Randomized, Open-label Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With the Capsid Inhibitor Lenacapavir as Long-Acting Treatment …
CONDITION: Other
GENDER: All
AGE GROUP: 18 to 65 years
TRIAL STATUS: Active, not recruiting
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide …
CONDITION: Inflammatory and Immune System
GENDER: All
AGE GROUP: 18 and above
TRIAL STATUS: Completed
This study is being done to see how well a new HIV treatment works compared to current standard treatment. Researchers are testing a single tablet that combines bictegravir (BIC) and …
CONDITION: Inflammatory and Immune System
GENDER: All
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting
This study is for people living with HIV whose treatment is already keeping the virus under control. Researchers are testing whether switching to new medicines, bictegravir and lenacapavir (together in …
CONDITION: Inflammatory and Immune System
GENDER: All
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting
This study is testing whether people with HIV whose virus is already well controlled can safely switch from their current daily HIV medicines to a new once-a-week pill (islatravir/lenacapavir).
CONDITION: Inflammatory and Immune System
GENDER: All
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting
This is a large final-stage (Phase 3) clinical trial testing whether people living with HIV, who already have their virus under control on the standard daily HIV pill (Biktarvy® – …
CONDITION: Inflammatory and Immune System
GENDER: Both males and females
AGE GROUP: 18 and above
TRIAL STATUS: Active, not recruiting
REZOLV3R is a randomised, double-blind, multi-centre trial treating symptomatic patients with recurrent malignant ascites suitable for paracentesis and a paracentesis-free interval of 28 days or less. The aim of the …
CONDITION: Cancer
GENDER: Both males and females
AGE GROUP: 18 and above
TRIAL STATUS: Recruiting
Australian researchers are testing a potential new treatment for obesity and weight-related comorbidities in adolescents. This is a 76 week study and may include up to 23 visits. Your adolescent …
CONDITION: Diet and Nutrition
GENDER: All
AGE GROUP: 12 to 17 years
TRIAL STATUS: Recruiting
The objective of ASPIRE-AF is to assess the feasibility of a randomized controlled trial of non-vitamin K oral anticoagulants versus usual care in patients with perioperative atrial fibrillation (AF) after …
CONDITION: Cardiovascular
GENDER: Both males and females
AGE GROUP: 55 and above
TRIAL STATUS: Recruiting
This international, multicentre, pragmatic, double-blind, placebo-controlled, randomised trial of TxA versus placebo will enrol 3,300 patients throughout Australia and internationally. This is an effectiveness trial – some elements of the …
CONDITION: Anaesthesiology
GENDER: Both males and females
AGE GROUP: 18 and above
TRIAL STATUS: Recruiting
Australian researchers are testing a potential new treatment for chronic skin wounds. This is a 10 week study with at least 8 separate visits. You will be treated at no …
CONDITION: Skin
GENDER: All
AGE GROUP: 18 and above
TRIAL STATUS: Recruiting
This study aims to test a potential new treatment for IBS using a Gastrointestinal Reprogramming Product (GaRP) that has been designed by Anatara to address the key underlying factors associated …
CONDITION: Oral and Gastrointestinal
GENDER: Both males and females
AGE GROUP: 18 to 65 years
TRIAL STATUS: Not yet recruiting
Australian researchers are testing a potential new treatment for atopic dermatitis (eczema) in children. This is a 36 week study with at least 12 separate visits. Your child will be …
CONDITION: Skin
GENDER: All
AGE GROUP: 6 to 17 years
TRIAL STATUS: Recruiting
Aims: to document the efficacy and safety outcomes of SCS in persons with chronic, chemotherapy-induced peripheral neuropathy Types of chemotherapy: Taxotere, Oxaliplatin, Paclitaxel Primary outcome measure: % responder rate at …
CONDITION: Cancer
GENDER: Both males and females
AGE GROUP: 18 to 100 years
TRIAL STATUS: Recruiting
What is the study about? Are you interested in finding out how our microbiome (the DNA of all the ‘bugs’ that live on us and in us) can impact on …
CONDITION: Reproductive Health and Childbirth
GENDER: Females
AGE GROUP: 18 and above
TRIAL STATUS: Recruiting
Patients presenting to the emergency department with acute ischemic stroke, who are are eligible for standard intravenous thrombolytic therapy within 4.5 hours of stroke onset will be assessed for major …
CONDITION: Stroke
GENDER: Both males and females
AGE GROUP: 18 and above
TRIAL STATUS: Recruiting